---
title: "Gelteq Limited (GELS.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/GELS.US.md"
symbol: "GELS.US"
name: "Gelteq Limited"
industry: "Pharmaceuticals"
datetime: "2026-06-10T04:37:38.598Z"
locales:
  - [en](https://longbridge.com/en/quote/GELS.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/GELS.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/GELS.US.md)
---

# Gelteq Limited (GELS.US)

## Company Overview

Gelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals in the United States of America and Australia. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products. Gelteq Limited was incorporated in 2017 and is headquartered in Clayton, Australia.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.gelteq.com](https://www.gelteq.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-06-09T04:30:17.000Z

**Overall: C (0.49)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 105 / 194 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 182.20% |  |
| Net Profit YoY | -83.45% |  |
| P/B Ratio | 0.50 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 5142379.43 |  |
| Revenue | 267841.97 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -42.99% | E |
| Profit Margin | -1608.55% | E |
| Gross Margin | 72.07% | A |
| Revenue YoY | 182.20% | A |
| Net Profit YoY | -83.45% | E |
| Total Assets YoY | 1.20% | C |
| Net Assets YoY | 2.30% | C |
| Cash Flow Margin | 83.09% | C |
| OCF YoY | 182.20% | A |
| Turnover | 0.02 | E |
| Gearing Ratio | 26.41% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Gelteq Limited",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "182.20%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-83.45%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.50",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "5142379.43",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "267841.97",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-42.99%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-1608.55%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "72.07%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "182.20%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-83.45%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "1.20%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "2.30%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "83.09%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "182.20%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.02",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "26.41%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.20 | 113/194 | - | - | - |
| PB | 0.50 | 18/194 | 1.24 | 0.97 | 0.75 |
| PS (TTM) | 19.23 | 127/194 | 56.66 | 41.19 | 27.99 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/GELS.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/GELS.US/norm.md)
- [Related News](https://longbridge.com/en/quote/GELS.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/GELS.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**